Corvus Pharmaceuticals, Inc. Uncategorized Contracts & Agreements
12 Contracts & Agreements
- Description of Registrants Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on May 7, 2024)
- Open Market Sale Agreement, dated November 1, 2021, by and between Corvus Pharmaceuticals, Inc. and Jefferies LLC (Filed With SEC on March 10, 2022)
- Description of Registrants Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 25, 2021)
- Phase I/IB Combination Study Agreement, dated October 5, 2015, by and between Corvus Pharmaceuticals, Inc. and Genentech, Inc (Filed With SEC on October 29, 2020)
- Amendment No. 1 to the Phase 1b/II Combination Study Agreement dated December 20, 2017, by and between Corvus Pharmaceuticals, Inc. and Genentech, Inc (Filed With SEC on March 9, 2020)
- Amendment No. 2 to the Phase I/IB Combination Study Agreement, dated August 1, 2019, by and between Corvus Pharmaceuticals, Inc. and Genentech, Inc (Filed With SEC on March 9, 2020)
- Amendment No. 1 to the Phase I/IB Combination Study Agreement, dated December 20, 2017, by and between Corvus Pharmaceuticals, Inc. and Genentech, Inc (Filed With SEC on March 9, 2020)
- Description of Registrants Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 9, 2020)
- Offer Letter, dated as of January 7, 2019 by and between Corvus Pharmaceuticals, Inc. and Mehrdad Mobasher (Filed With SEC on March 7, 2019)
- Offer Letter, dated as of November 22, 2017 by and between Corvus Pharmaceuticals, Inc. and Daniel Hunt (Filed With SEC on March 1, 2018)
- [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with... (Filed With SEC on August 3, 2017)
- PHASE I/IB COMBINATION STUDY AGREEMENT BY AND BETWEEN GENENTECH, INC. AND CORVUS PHARMACEUTICALS, INC. (Filed With SEC on February 8, 2016)
